Cardiovascular Institute, Hospital Clinic, IDIBAPS, Barcelona, 08036, Spain.
Division of Cardiology, A.O.U. 'Policlinico-Vittorio Emanuele', University of Catania, Catania, 95124, Italy.
Future Cardiol. 2021 May;17(3):427-442. doi: 10.2217/fca-2020-0211. Epub 2021 Feb 3.
Cardiovascular disease manifestations (CVD) are the world's leading cause of death, and their impact on morbidity requires effective prevention strategies of recurrent adverse events. For decades, inflammation has been proposed as a key promoter for atherosclerosis and its complications. However, studies on the use of drugs to target the excess inflammation in CVD are limited. In 2017, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial confirmed the key role of inflammation on atherosclerotic disease. Canakinumab is a monoclonal antibody that blocks an inflammatory pathway mediated by IL-1β. The results of the CANTOS trial opened a new era of investigating new therapeutics targeting inflammation for CVD secondary prevention. This review presents the canakinumab's pharmacology, current clinical development status and regulatory perspectives.
心血管疾病表现（CVD）是全球主要死因，其对发病率的影响需要有效的预防策略来防止不良事件复发。几十年来，炎症一直被认为是动脉粥样硬化及其并发症的关键促进因素。然而，针对 CVD 中过度炎症使用药物的研究有限。2017 年，卡那单抗抗炎血栓结局研究（CANTOS）证实了炎症在动脉粥样硬化疾病中的关键作用。卡那单抗是一种单克隆抗体，可阻断由白细胞介素-1β介导的炎症通路。CANTOS 试验的结果开创了一个新的时代，即研究针对 CVD 二级预防的靶向炎症的新疗法。这篇综述介绍了卡那单抗的药理学、当前临床开发状况和监管视角。
